Please use this identifier to cite or link to this item:
Title: Theranostics in oncology: What radiologists want to know.
Authors: Ferdinandus, Justin
Fendler, Wolfgang Peter
Morigi, Joshua James
Fanti, Stefano
Citation: Copyright © 2021. Published by Elsevier B.V.
Eur J Radiol. 2021 Sep;142:109875. doi: 10.1016/j.ejrad.2021.109875. Epub 2021 Jul 26.
Abstract: Combination of radioligand imaging and therapy, so called radiotheranostics, is a novel tool of precision oncology with proven clinical value. In-depth knowledge of functional imaging nuances is critically needed for precise prognostication and guidance of management. Here, we review theranostic applications with up to Phase III type evidence for outcome improvement: Imaging and therapy of neuroendocrine neoplasms (NEN) exploiting high levels of somatostatin receptor (SSTR) expression and radiotheranostics of prostate cancer targeting the prostate specific membrane antigen (PSMA). This narrative review focusses on these two applications and elucidates patient selection and response assessment by radioligand scintigraphy and/or positron emission tomography. Furthermore, we provide a brief outlook on future applications for novel targets outside of NEN and prostate cancer.
Click to open Pubmed Article:
Journal title: European journal of radiology
Volume: 142
Pages: 109875
Publication Date: 2021-09
Type: Journal Article
DOI: 10.1016/j.ejrad.2021.109875
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing


PubMed References

Who's citing